Bispecific aptamers can simultaneously bind two different cell surface receptors on two different cells, such as cancer cells and lymphocytes, inducing enhanced anti-cancer immunity by targeting both cancer cells and lymphocytes simultaneously (10). This evidence concerns the gene CD177 and cancer.